Publications

BibTex format

@article{Abbara:2015:10.1210/jc.2015-2332,
author = {Abbara, A and Jayasena, CN and Christopoulos, G and Narayanaswamy, SN and Izzi-Engbeaya, C and Nijher, G and Comninos, A and Peters, D and Buckley, A and Ratnasabapathy, R and Prague, JK and Salim, R and Lavery, SA and Bloom, SR and Szigeti, M and Ashby, D and Trew, G and Dhillo, WS},
doi = {10.1210/jc.2015-2332},
journal = {Journal of Clinical Endocrinology and Metabolism},
pages = {3322--3331},
title = {Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy},
url = {http://dx.doi.org/10.1210/jc.2015-2332},
volume = {100},
year = {2015}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Context:In Vitro Fertilization (IVF) treatment is an effective therapy for infertility, but can result in the potentially life-threatening complication ‘ovarian hyperstimulation syndrome’ (OHSS).Objective:To investigate whether kisspeptin-54 can be used to effectively and safely trigger oocyte maturation in women undergoing IVF treatment at high risk of developing OHSS.Design:Phase 2 multi-dose open label randomized clinical trial carried out during 2013–2014.Setting:Hammersmith Hospital IVF unit, London, UK.Patients:Sixty women at high risk of developing OHSS                                     Intervention:Following a standard recombinant FSH/GnRH antagonist protocol, patients were randomized to receive a single injection of kisspeptin-54 to trigger oocyte maturation using an adaptive design for dose allocation (3.2nmol/kg, n=5; 6.4nmol/kg, n=20; 9.6nmol/kg, n=15; 12.8nmol/kg, n=20). Oocytes were retrieved 36hrs after kisspeptin-54 administration, assessed for maturation, and fertilized by intra-cytoplasmic sperm injection (ICSI) with subsequent transfer of one or two embryos. Women were routinely screened for the development of OHSS.Main Outcome Measure:Oocyte maturation was measured by oocyte yield (percentage of mature oocytes retrieved from follicles ≥14mm on ultrasound). Secondary outcomes include rates of OHSS and pregancy.                              Results:Oocyte maturation occurred in 95% of women. Highest oocyte yield (121%) was observed following 12.8nmol/kg kisspeptin-54, which was +69% (CI -16%,+153%) greater than following 3.2nmol/kg. At all doses of kisspeptin-54, biochemical pregnancy, clinical pregnancy and live birth rates per transfer (n=51) were 63%, 53% and 45%, respectively. Highest pregnancy rates were observed following 9.6nmol/kg kisspeptin-54 (85%, 77% and 62%, respectively). No woman developed moderate, severe or critical OHSS.Conclusion:Kisspeptin-54 is a promising approach to effectively and safely trigger oocyte
AU  - Abbara,A
AU  - Jayasena,CN
AU  - Christopoulos,G
AU  - Narayanaswamy,SN
AU  - Izzi-Engbeaya,C
AU  - Nijher,G
AU  - Comninos,A
AU  - Peters,D
AU  - Buckley,A
AU  - Ratnasabapathy,R
AU  - Prague,JK
AU  - Salim,R
AU  - Lavery,SA
AU  - Bloom,SR
AU  - Szigeti,M
AU  - Ashby,D
AU  - Trew,G
AU  - Dhillo,WS
DO  - 10.1210/jc.2015-2332
EP  - 3331
PY  - 2015///
SN  - 0368-1610
SP  - 3322
TI  - Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy
T2  - Journal of Clinical Endocrinology and Metabolism
UR  - http://dx.doi.org/10.1210/jc.2015-2332
UR  - http://hdl.handle.net/10044/1/26253
VL  - 100
ER  -

Download

ProfessorDeborahAshby

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)